In a regulatory filing after trading hours yesterday, the company announced that the group's injectables manufacturing facility at Zydus Biotech Park in Changodar, Ahmedabad, Gujarat, underwent United States Food and Drug Administration (US FDA) inspection from 5th June to 13th June, 2023.

The current good manufacturing practice (CGMP) inspection at the said facility was concluded with nil observations.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.

The scrip rose 0.40% to currently trade at Rs 519.75 on the BSE.